metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)

versus sunitinib

nivolumab plus ipilimumab

• Lancet Oncol. 2019; 20:1370-1385
• N. Engl. J. Med. 2018; 378:1277-1290
• J Immunother Cancer 2020 Jul;8(2):e000891.
• Jpn J Clin Oncol 2020 Jan 24;50(1):12-19.
• Immunotherapy 2020 Jan;12(1):37-51.
• Lancet Oncol 2019 Feb;20(2):297-310.
• Eur Urol 2022; 81:266-271-.
• Cancer 2022; 128:2085-2097-.
• J Immunother Cancer 2022; 10:333-340-.

• demonstrated 37 % decrease in deaths (OS) (PE)
• inconclusive 18 % decrease in progression or deaths (PFS) (PE)
• suggested 34 % decrease in deaths (OS) (extension)
• suggested 23 % decrease in PFS (extension)
more...

• Lancet Oncol. 2019; 20:1370-1385
• N. Engl. J. Med. 2018; 378:1277-1290
• J Immunother Cancer 2020 Jul;8(2):e000891.
• Jpn J Clin Oncol 2020 Jan 24;50(1):12-19.
• Immunotherapy 2020 Jan;12(1):37-51.
• Lancet Oncol 2019 Feb;20(2):297-310.

• statistically significant 1.2-fold increase in progression or deaths (PFS)

• Lancet Oncol. 2019; 20:1370-1385
• N. Engl. J. Med. 2018; 378:1277-1290
• Urologe A 2015; 54:1443-5
• J Immunother Cancer 2020 Jul;8(2):e000891.
• Jpn J Clin Oncol 2020 Jan 24;50(1):12-19.
• Clin Cancer Res 2020 Sep 1.

• suggested 32 % decrease in deaths (OS)
• suggested 29 % decrease in deaths (OS) (extension)
• suggested 15 % decrease in PFS (extension)